📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
56 announcements match the current filters (relevance ≥ 5).
Mukka Proteins to raise ₹47 crore through issuance of 2 crore convertible warrants
Mukka Proteins Limited has issued a postal ballot notice to seek shareholder approval for a preferential issue of up to 2,00,00,000 convertible warrants. The warrants are priced at ₹23.50 each, aiming to raise a total of ₹47 crore from 15 non-promoter investors. Each warrant is convertible into one equity share of face value ₹1 within 18 months from the date of allotment. The e-voting period for this special resolution is scheduled from June 13, 2026, to July 12, 2026.
Key Highlights
Proposed issuance of 2,00,00,000 convertible warrants at an issue price of ₹23.50 per warrant.
Total fundraise size is capped at ₹47,00,00,000 (₹47 crore) targeting 15 non-promoter entities.
Warrants are convertible into equity shares at a premium of ₹22.50 per share within 18 months.
The relevant date for floor price determination is fixed as June 12, 2026.
Remote e-voting for shareholders concludes on July 12, 2026, with results expected within two working days.
👀 What to Watch
Investors should monitor the final approval of the resolution and the subsequent conversion of warrants, as it will lead to equity dilution but provides growth capital for the company.
Mukka Proteins to Acquire 51% Stake in Delta Marine Products for Rs 11.10 Crore
Mukka Proteins Limited has approved a strategic investment to acquire a 51% controlling stake in Delta Marine Products, a partnership firm engaged in manufacturing fish meal and fish oil. The acquisition will cost up to Rs 11.10 crore, to be paid in cash through capital contributions in one or more tranches. While the target entity reported a significant turnover of Rs 28.17 crore in FY 2024-25, it recorded a net loss of Rs 19.73 lakhs. The transaction is expected to be completed by September 30, 2026, aiming to enhance Mukka's production capacity and market reach.
Key Highlights
Acquisition of a 51% majority stake in Delta Marine Products for a consideration not exceeding Rs 11.10 crore.
Target entity's turnover surged from Rs 3.64 crore in FY24 to Rs 28.17 crore in FY25, showing rapid scale-up.
The deal is a strategic horizontal integration as both entities operate in the fish meal and fish oil industry.
The acquisition is expected to be finalized by September 30, 2026, via cash-based capital contributions.
Delta Marine Products reported a PAT loss of Rs 19.73 lakhs for FY 2024-25, which Mukka aims to improve through operational optimization.
👀 What to Watch
Investors should view this as a growth-oriented move that expands Mukka's core capacity, though they should monitor the company's ability to turn the target entity profitable. The rapid revenue growth of Delta Marine suggests strong market demand for its products.
Mukka Proteins to Acquire 51% Stake in Aqua Marine for Rs 15 Crore
Mukka Proteins Limited has approved a strategic investment to acquire a 51% controlling stake in Aqua Marine, a partnership firm involved in manufacturing fish meal and fish oil. The acquisition will cost up to Rs 15 crore, to be paid in cash via capital contributions in one or more tranches. Aqua Marine reported a turnover of Rs 32.15 crore for FY 2024-25, which is a significant drop from its FY 2023-24 turnover of Rs 54.67 crore. The deal is expected to be completed by September 30, 2026, and aims to expand Mukka's production capacity and market reach.
Key Highlights
Acquisition of 51% stake in Aqua Marine for a total consideration not exceeding Rs 15 crore.
Target entity is in the same line of business (fish meal and fish oil), facilitating vertical integration.
Aqua Marine's FY25 turnover was Rs 32.15 crore with a PAT of approximately Rs 10.68 lakhs.
The investment will be made in cash through capital contributions in tranches by September 30, 2026.
Strategic move intended to optimize operational processes and expand core business capacity.
👀 What to Watch
Investors should view this as a strategic expansion move, though they should monitor the target's declining turnover and low profitability margins to ensure the acquisition becomes accretive.
Mukka Proteins to Raise ₹47 Cr via Warrants and Acquire 51% Stake in Two Firms for ₹26.1 Cr
Mukka Proteins Limited has approved a preferential issue of 2,00,00,000 fully convertible warrants at ₹23.50 per warrant, aiming to raise ₹47 crore from non-promoter investors. The company is simultaneously deploying capital to acquire 51% stakes in two partnership firms, Delta Marine Products and Aqua Marine, for ₹11.10 crore and ₹15 crore respectively. These strategic investments are focused on expanding the company's core fish meal and fish oil business and optimizing production efficiency. The warrants are convertible into equity shares within 18 months, which will eventually increase the company's paid-up equity capital to ₹32 crore.
Key Highlights
Approved issuance of 2 crore fully convertible warrants at ₹23.50 each, aggregating to ₹47 crore.
Acquiring 51% controlling stake in Delta Marine Products for a consideration up to ₹11.10 crore.
Acquiring 51% controlling stake in Aqua Marine for a consideration up to ₹15.00 crore.
Target entities Delta Marine and Aqua Marine reported FY25 turnovers of ₹28.17 crore and ₹32.15 crore respectively.
The acquisitions are expected to be completed by September 30, 2026, to drive capacity expansion.
👀 What to Watch
Investors should view this as a growth-oriented move that expands the company's manufacturing footprint; however, they should monitor the post-acquisition integration and the impact on consolidated profitability.
Mukka Proteins to raise ₹47 Cr via Warrants; acquires 51% stake in two firms for ₹26.1 Cr
Mukka Proteins has approved raising ₹47 crore through the issuance of 2 crore convertible warrants to non-promoter investors at ₹23.50 per warrant. The company is also aggressively expanding by acquiring a 51% stake in two fish meal manufacturing firms, Delta Marine Products and Aqua Marine, for a combined investment of up to ₹26.1 crore. These strategic moves are intended to enhance production capacity and market reach, with the acquisitions slated for completion by September 30, 2026. The warrants are convertible into equity shares within 18 months, which will eventually increase the company's paid-up capital to ₹32 crore.
Key Highlights
Approved issuance of 2,00,00,000 fully convertible warrants at ₹23.50 each to raise ₹47 crore.
Acquiring 51% stake in Delta Marine Products for up to ₹11.10 crore (FY25 Turnover: ₹28.17 Cr).
Acquiring 51% stake in Aqua Marine for up to ₹15 crore (FY25 Turnover: ₹32.15 Cr).
Warrants are convertible into equity shares within 18 months at a premium of ₹22.50 per share.
The investments are aimed at capacity expansion and optimization of operational processes in the core fish meal business.
👀 What to Watch
The capital infusion and strategic acquisitions indicate a strong growth trajectory; investors should monitor the successful integration of these firms and their impact on consolidated margins.
CARE Downgrades Mukka Proteins to 'BBB-' Over Stretched Working Capital; Outlook Negative
CARE Ratings has downgraded Mukka Proteins' long-term bank facilities to 'BBB-' from 'BBB' while maintaining a 'Negative' outlook. The downgrade stems from a prolonged working capital cycle of 189 days and high inventory levels, which have led to a 95% utilization of bank limits. While FY26 revenue grew 45% to ₹1,468 crore, debt coverage metrics have weakened, with Total Debt/GCA rising to 10.84x from 7.35x. The company remains exposed to volatile fish meal prices and seasonal raw material availability.
Key Highlights
Long-term rating downgraded to CARE BBB- (Negative) for ₹495 crore in bank facilities.
Working capital cycle stood at 189 days in FY26, significantly higher than the historical <70 days.
Revenue grew 45% YoY to ₹1,468 crore in FY26, but interest coverage dropped to 2.48x.
Total Debt to Gross Cash Accruals (TD/GCA) deteriorated to 10.84x from 7.35x YoY.
Average utilization of working capital limits reached 95%, indicating tight liquidity.
👀 What to Watch
Investors should exercise caution as the downgrade reflects rising financial risk and liquidity pressure. Watch for a reduction in inventory levels and improvement in cash flows as key recovery signals.
Mukka Proteins Targets ₹3,000+ Cr Revenue by FY30; FY26 Revenue at ₹1,449 Cr
Mukka Proteins reported FY26 revenue of ₹1,449 crore and has set an ambitious target to exceed ₹3,000 crore by FY30, representing a 2x growth in four years. The company maintains a dominant 25-30% market share in the Indian fishmeal and fish oil segment, with exports contributing 79.7% of total revenue. Strategic diversification into insect protein and waste management is underway, supported by carbon credit approvals for 1,200 TPD and a ₹474.89 crore leachate treatment order. The company is also expanding its global footprint with a new facility in Oman and recent acquisitions to strengthen its wholly-owned subsidiaries.
Key Highlights
FY26 Revenue reached ₹1,449 crore with a strategic target to reach ₹3,000+ crore by FY30
Maintains a leading 25-30% market share in India's fishmeal and fish oil industry with 2,91,720 MT/year capacity
Export-heavy business model with 79.7% of FY26 revenue coming from international markets across 25+ countries
Diversifying into waste management with a significant ₹474.89 crore leachate treatment contract from BSWML
Secured carbon credit approvals for 1,200 TPD, aligning with global ESG trends and potential valuation re-rating
👀 What to Watch
Investors should monitor the execution of the new Oman facility and the scaling of the high-margin insect protein vertical. The ambitious FY30 revenue guidance and transition to an integrated protein platform suggest strong long-term growth potential.
Mukka Proteins FY26 Revenue Surges 44% to ₹1,449.5 Cr; Q4 PAT Jumps 52.6% YoY
Mukka Proteins reported a strong FY26 with consolidated revenue growing 44% YoY to ₹1,449.5 crore, supported by robust global demand and improved pricing. While full-year PAT grew 18.7% to ₹57.1 crore, the fourth quarter saw significant margin expansion with Q4 PAT rising 52.6% YoY to ₹21.4 crore. The company is aggressively scaling its global footprint with an upcoming facility in Oman and a new subsidiary in Sri Lanka. Strategic wins like the Bengaluru animal waste management contract and MarinTrust alignment further strengthen its ESG-led growth profile.
Key Highlights
FY26 Revenue increased 44% YoY to ₹1,449.5 Cr, while EBITDA grew 30.9% to ₹145.3 Cr.
Q4 FY26 EBITDA margins expanded by 421 bps YoY to 12.9%, leading to a 52.6% surge in quarterly PAT.
Upcoming 21,249 sq. mt facility in Oman and new investment in Sri Lanka to drive international growth.
Secured a strategic contract for integrated animal waste management in Bengaluru from BBMP/BSWML.
Maintains a dominant 25-30% market share in India's fishmeal and fish oil segment.
👀 What to Watch
Investors should monitor the commissioning of the Oman facility and the execution of the Bengaluru waste contract as key growth catalysts. The significant margin improvement in Q4 suggests better operational efficiency and pricing power in the marine protein segment.
Mukka Proteins to Invest ₹2.5 Crore for 49% Stake in New Sri Lankan Entity
Mukka Proteins has approved the incorporation of a new overseas entity, Lanka Bio Proteins Private Limited, in Sri Lanka to expand its international footprint. The company will invest up to ₹2.5 crore (approximately 9.75 crore Sri Lankan Rupees) to acquire a 49% equity stake in the new venture. The entity will focus on the manufacturing and trading of marine products, aligning with Mukka's core business. The total proposed capital for the new entity is approximately ₹3.60 crore, with completion expected by December 31, 2026.
Key Highlights
Investment of up to ₹2.5 crore for a 49% stake in the newly incorporated Sri Lankan entity.
Total proposed capital of the target entity, Lanka Bio Proteins Private Limited, is ₹3.60 crore.
The venture focuses on manufacturing and trading marine products and allied activities.
Strategic move to expand international business operations and strengthen global presence.
The acquisition and incorporation process is slated for completion by December 31, 2026.
👀 What to Watch
Investors should monitor the progress of this international expansion as it could diversify revenue streams and enhance long-term growth. The relatively small investment size suggests a low-risk entry into the Sri Lankan market.
Mukka Proteins to Invest ₹2.5 Crore for 49% Stake in New Sri Lankan Entity
Mukka Proteins Limited has approved the incorporation of a new overseas entity, Lanka Bio Proteins Private Limited, in Sri Lanka. The company will invest up to ₹2.5 crore (approximately 9.75 crore Sri Lankan Rupee) to acquire a 49% equity stake in the new venture. This entity will focus on the manufacturing and trading of marine products, aligning with Mukka's core business. The move is strategically designed to expand the company's international footprint and is expected to be completed by December 31, 2026.
Key Highlights
Proposed investment of up to ₹2.5 crore for a 49% stake in Lanka Bio Proteins Private Limited.
The new entity will have a total proposed capital of approximately ₹3.60 crore.
Focus area includes manufacturing and trading of marine products and allied activities in Sri Lanka.
The transaction is a cash consideration and is expected to be completed by December 31, 2026.
Strategic expansion aimed at strengthening international business operations and marine sector presence.
👀 What to Watch
Investors should view this as a positive step towards geographical diversification and international growth. Monitor the progress of the incorporation and subsequent operational updates from the Sri Lankan market.
Mukka Proteins Board Approves Raising ₹75 Crores via Non-Convertible Debentures
The Board of Mukka Proteins has approved the issuance of secured, rated, and listed Non-Convertible Debentures (NCDs) totaling ₹75 crores. The fundraise is divided into two parts: an immediate ₹25 crore tranche with a 12% annual coupon and a 15-month tenure, and a broader ₹50 crore authorization for future tranches. These securities will be issued on a private placement basis and listed on the BSE Wholesale Debt Market. This move indicates a strategic push to secure debt capital, likely for working capital or expansion needs.
Key Highlights
Total fundraise of ₹75 crores approved via secured, rated, and listed NCDs.
First tranche of ₹25 crores carries a 12.00% annual coupon rate with monthly interest payments.
The ₹25 crore NCDs have a short-term tenure of 15 months from the date of allotment.
Additional ₹50 crores authorized to be raised in one or more tranches via private placement.
NCDs will be secured against current assets or other company assets as per transaction documents.
👀 What to Watch
Investors should monitor the company's debt-to-equity ratio and ensure the 12% interest cost is offset by higher returns from the deployed capital. It is important to track the specific end-use of these funds in upcoming quarterly reports.
Mukka Proteins FY26 Revenue Up 39% to ₹1,229 Cr; Board OKs ₹75 Cr Fundraise & SL Expansion
Mukka Proteins reported a robust 39% YoY growth in annual revenue from operations, reaching ₹1,229.20 crore for FY26. The company's profit before tax also improved to ₹58.78 crore from ₹52.58 crore in the previous fiscal year. To support this growth, the board approved a total fundraise of ₹75 crore through Non-Convertible Debentures (NCDs). Additionally, the company is expanding its footprint with a new 49% stake in a Sri Lankan entity and a 51% stake in a domestic joint venture.
Key Highlights
Annual revenue from operations grew 38.6% YoY to ₹1,229.20 crore in FY26 compared to ₹886.74 crore in FY25.
Board approved fundraising of up to ₹75 crore via private placement of secured, rated, listed NCDs in two tranches.
Strategic international expansion into Sri Lanka with an investment of up to ₹2.50 crore for a 49% stake in Lanka Bio Proteins.
Standalone Profit Before Tax (PBT) for the full year ended March 31, 2026, stood at ₹58.78 crore.
Approved a 51% profit-sharing investment in a new partnership firm named MPL FC HRC JV.
👀 What to Watch
The company is showing strong top-line growth and aggressive expansion plans; investors should monitor the successful execution of the Sri Lankan venture and the impact of new debt on the balance sheet.
Mukka Proteins Acquires 100% Stake in Haris Marine Products for Rs. 19.64 Lakhs
Mukka Proteins Limited has completed the acquisition of 2,000 equity shares of Haris Marine Products Private Limited (HMPPL), making it a wholly-owned subsidiary effective March 30, 2026. The acquisition was executed for a total cash consideration of Rs. 19.64 Lakhs. While HMPPL reported nil turnover for the last two financial years, it surprisingly recorded a Profit After Tax (PAT) of Rs. 2.24 Crores in FY 2024-25. This strategic move is intended to expand Mukka's core business in the fish meal and fish oil industry.
Key Highlights
Acquired 2,000 equity shares at Rs. 100 face value for a total of Rs. 19.64 Lakhs.
Haris Marine Products (HMPPL) has become a 100% Wholly Owned Subsidiary of Mukka Proteins.
Target entity reported a PAT of Rs. 2.24 Crores for FY 2024-25 despite reporting nil turnover.
HMPPL previously had a turnover of Rs. 50.95 Crores in FY 2022-23 before dropping to nil in subsequent years.
The acquisition is a strategic investment to expand the company's core fish meal and fish oil business.
👀 What to Watch
Investors should monitor the integration of this subsidiary and seek clarity on how the entity maintains high profitability despite nil turnover. The low acquisition cost relative to the target's PAT suggests a value-accretive deal for the parent company.
Mukka Proteins to Acquire Remaining 2% Stake in Haris Marine Products for ₹19.64 Lakhs
Mukka Proteins Limited has entered into a Share Purchase Agreement to acquire the remaining 2% equity stake in Haris Marine Products Private Limited. The company currently holds a 98% stake and will pay a total consideration of INR 19.64 Lakhs for the final 2,000 shares. This acquisition will make Haris Marine Products a wholly-owned subsidiary of Mukka Proteins. The transaction is a related party transaction involving the company's promoters but has been conducted at arm's length.
Key Highlights
Acquisition of 2,000 equity shares representing the final 2% stake in Haris Marine Products
Total cash consideration for the transaction is INR 19.64 Lakhs
Mukka Proteins' ownership in the subsidiary will increase from 98% to 100%
The deal involves promoters as sellers and is executed at arm's length
👀 What to Watch
This is a minor consolidation of a subsidiary and has a negligible financial impact due to the small deal size. Investors should view it as a positive move towards simplifying the corporate structure.
Mukka Proteins Achieves MarinTrust Improver Programme Compliance for 3 Years
Mukka Proteins Limited has received a confirmation letter from Global Trust Certification (NSF) for compliance with the MarinTrust Improver Programme for Responsible Supply of Marine Ingredients. This certification, valid for a period of 3 years, recognizes the company's use of Fishery Improvement Project (FIP) raw materials. The compliance reinforces the company's commitment to sustainability, traceability, and responsible sourcing in its marine ingredient supply chain. This development is expected to strengthen buyer confidence and enhance the company's competitive positioning in global markets.
Key Highlights
Compliance confirmed by Global Trust Certification Ltd, Ireland, for the MarinTrust Improver Programme.
The certification is valid for a period of 3 years, ensuring long-term supply chain recognition.
Enables the company to source marine ingredients produced using Fishery Improvement Project (FIP) raw materials.
Provides assurance to global buyers regarding traceability and responsible sourcing practices.
👀 What to Watch
Investors should view this as a positive ESG development that improves the company's ability to cater to international markets with strict sustainability standards. Monitor if this certification leads to higher-margin export orders or new global partnerships.
Mukka Proteins Completes Acquisition of Ento Proteins; Becomes Wholly Owned Subsidiary
Mukka Proteins Limited has finalized the acquisition of 1,000 equity shares of Ento Proteins Private Limited (EPPL) for a total cash consideration of Rs. 32.30 Lakhs. Following this transaction, EPPL has become a wholly-owned subsidiary of the company effective February 23, 2026. EPPL is a manufacturer of insect meal and insect oil, reporting a turnover of Rs. 7.46 Crores and a PAT of Rs. 49.47 Lakhs for FY 2024-25. This acquisition aligns with Mukka Proteins' strategic plan to expand its presence in the alternate proteins market.
Key Highlights
Acquired 1,000 equity shares for a total cash consideration of Rs. 32.30 Lakhs
Ento Proteins (EPPL) is now a 100% wholly-owned subsidiary of Mukka Proteins
EPPL reported a turnover of Rs. 7.46 Crores and PAT of Rs. 49.47 Lakhs for FY 2024-25
Target company specializes in the niche manufacturing of insect meal and insect oil
Strategic expansion into the high-growth alternate proteins business segment
👀 What to Watch
Investors should monitor the integration of this niche alternate protein business and its contribution to the consolidated bottom line. The acquisition is small but strategically sound for long-term diversification.
Mukka Proteins to Acquire Remaining 25.99% Stake in Ento Proteins for ₹32.3 Lakhs
Mukka Proteins Limited has entered into a Share Purchase Agreement (SPA) to acquire the remaining 25.99% equity stake in its subsidiary, Ento Proteins Private Limited. The company currently holds 74.01% of the investee company and will move to 100% ownership upon completion. The total cash consideration for the 1,000 equity shares is ₹32,30,000. This acquisition will result in Ento Proteins becoming a wholly-owned subsidiary and will terminate previous shareholder agreements.
Key Highlights
Acquisition of remaining 25.99% stake in Ento Proteins Private Limited
Total cash consideration of INR 32,30,000 for 1,000 equity shares
Ownership stake increases from 74.01% to 100%, making it a wholly-owned subsidiary
Rescission and termination of the Shareholders’ Agreement dated September 7, 2021
Transaction involves acquisition from Holocene Ecosolutions Private Limited
👀 What to Watch
This is a routine consolidation of a subsidiary which simplifies the corporate structure. Investors should view this as a minor positive move to gain full control over the investee company's operations.
Mukka Proteins Q3 Revenue Jumps 115% YoY; Bags ₹475 Cr Order for Waste Management
Mukka Proteins reported a robust Q3 FY26 with revenue surging 115% YoY to ₹653.5 crore, driven by strong export demand and operational scaling. The company secured a major ₹474.89 crore order for leachate treatment, marking a significant step in its waste-to-value diversification strategy. 9M FY26 revenue reached ₹1,068.9 crore, already exceeding the total FY25 revenue of ₹887 crore. Management has set an ambitious target of ₹2,500+ crore revenue by FY30, supported by capacity expansions and carbon credit initiatives.
Key Highlights
Q3 FY26 revenue grew 115% YoY to ₹653.5 crore; 9M FY26 revenue reached ₹1,068.9 crore.
Secured a ₹474.89 crore order from BSWML for legacy leachate treatment over 4 years.
Carbon credit portfolio advanced with 300 TPD operations listed on Verra Registry and expansion to 1,000 TPD approved.
Board approved increasing stakes in Ento Proteins and Haris Marine Products to 100% ownership.
Export revenue share stands at 75.7% for 9M FY26, with a 25-30% domestic market share.
👀 What to Watch
Investors should monitor the execution of the large waste management contract and the progress of carbon credit issuance, which could significantly boost margins. The company's aggressive FY30 revenue target suggests strong management confidence in the integrated protein and sustainability platform.
Mukka Proteins Q3 Revenue Surges 115% to ₹653.5 Cr; Secures ₹475 Cr Waste Management Order
Mukka Proteins reported a massive 115.57% YoY revenue growth in Q3 FY26, reaching ₹653.50 crore, driven by global fishmeal supply shortages and price recovery. While revenue more than doubled, EBITDA margins compressed significantly to 8.14% from 15.73% in the previous year's quarter. A major highlight is the strategic diversification into waste management with a new ₹474.89 crore order for legacy leachate treatment in Bengaluru. The company is also consolidating its subsidiaries and expanding its carbon credit-linked waste processing capacity to 1,000 TPD.
Key Highlights
Q3 FY26 Revenue grew 115.57% YoY to ₹653.50 crore, while 9M FY26 revenue reached ₹1,068.85 crore.
Secured a large-scale order worth ₹474.89 crore for scientific treatment of legacy leachate from BSWML.
EBITDA stood at ₹53.21 crore with margins at 8.14%, reflecting a decline from 15.73% in the previous year.
Received incremental approval to expand BSF-driven wet-waste processing from 300 TPD to 1,000 TPD.
Consolidating ownership to 100% in Haris Marine Products and Ento Proteins to streamline operations.
👀 What to Watch
Investors should focus on the massive revenue scale-up and the significant diversification into high-margin waste management services which provides long-term visibility. However, the sharp contraction in EBITDA margins requires monitoring to ensure the company can pass on costs or optimize operations effectively.
Mukka Proteins to Acquire Remaining 25.99% Stake in Ento Proteins for Rs 32.3 Lakhs
Mukka Proteins has approved the acquisition of an additional 1,000 equity shares in its subsidiary, Ento Proteins Private Limited (EPPL), for Rs 32.30 lakhs. This transaction will increase Mukka's stake from 74.01% to 100%, making EPPL a wholly-owned subsidiary. EPPL is a niche manufacturer of insect meal and insect oil, reporting a turnover of Rs 7.46 crore and a PAT of Rs 49.47 lakhs for FY 2024-25. The move is part of Mukka's strategic plan to expand its presence in the alternate proteins market.
Key Highlights
Acquisition of 1,000 equity shares to increase shareholding from 74.01% to 100%
Total cash consideration for the additional stake is Rs 32.30 lakhs
EPPL turnover grew from Rs 4.72 crore in FY23 to Rs 7.46 crore in FY25
Target entity EPPL reported a profit after tax (PAT) of Rs 49.47 lakhs in FY 2024-25
The acquisition is expected to be completed by June 30, 2026
👀 What to Watch
Investors should note this strategic consolidation in the high-growth alternate protein segment, which could provide long-term synergy benefits. The acquisition is priced reasonably relative to EPPL's profitability and revenue growth.
